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Factors that Lead to the 
Immunotherapy Gap in Multiple 
Sclerosis Testing
 by Karthika Solai
I n t r o d u c t i o n
Multiple sclerosis is a disease that affects the central nervous system. 
Most doctors and scientists believe that it is an autoimmune disease. Sim-
ply put, the immune system attacks the nerves in a person’s body, there-
by causing myelin damage, inflammation, and neurodegeneration. The 
plaque that then builds up on the nerves is scar tissue created when the 
wounds made by the immune system heal. It is this plaque that inhibits 
communication between the axons in the body and causes the symptoms 
of MS, which includes problems with movement, pain, vision problems, 
trouble swallowing, fatigue, and heat sensitivity (Baker et al., 2011, p. 647). 
There are several different types or stages of MS. The most common 
type of multiple sclerosis is relapsing remitting. In relapsing remitting, the 
patient has episodes of neurological deficits that then repair themselves. 
However, the patient may not gain back complete functionality of their 
facilities following every relapse. Another type of MS is primary progres-
sive multiple sclerosis, which is characterized by a gradual accumulation 
of disability. There may be times when disability does not accumulate as 
quickly, but the patient never fully recovers. A third form of MS is sec-
ondary progressive multiple sclerosis, which is characterized by having 
two phases. The relapsing remitting phase occurs first and is followed 
by phase that resembles primary progressive MS (Steinman and Zamvil, 
2005, p. 566). 
Scientists replicate these types of MS in model systems for two primary 
research purposes. First, no therapies may be tested on humans before 
they are tested on animals first. Second, humans are often bad test sub-
jects for MS research. The effects of multiple sclerosis can best be seen in 
the spinal cord, and this form of human tissue cannot be examined while 
the patient is still alive without causing permanent damage. There is the 
chance of studying the spinal cords of the deceased, but there is often a 
limited sample size. In addition, a sample from the deceased will most like-
ly only provide information on the later stages of MS. Conversely, many 
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of the therapies for MS function best at earlier stages. Therefore, spinal 
cord samples of the deceased would not be of much use. Instead, animal 
models are used for testing (Baker et al., 2011, p. 647). Although they are 
more easily accessible, animal models, like human models, have both ben-
efits and pitfalls.
T h e  A n i m a l  M o d e l  f o r  M S
There are many different types of animal models for MS. However, 
the most prevalent type used by researchers is the murine (mouse or rat) 
experimental autoimmune encephalomyelitis (EAE) model. EAE is an in-
duced brain inflammation disease that reflects “a spectrum of neurological 
disorders in laboratory animals that is used to model multiple sclerosis” 
(Baker et al., 2011, p. 647). This model can reflect the complexity of mul-
tiple sclerosis because the symptoms manifested depend on the strain of 
mice used for testing (Teixeria, 2005, p. 128).  The EAE model was de-
veloped by injecting segments of inflamed spinal cord or brain tissue from 
one species into a different animal species. Symptoms manifested due to 
the animals’ genetic background and experimental parameters, such as the 
source and mode of application of the antigen (Mix et al., 2010, p. 387)
Scientists later improved this method through co-injection with Fre-
und’s complete adjuvant (CFA) to boost inflammation effects of various 
antigens (Mix et al., 2010, p. 387). CFA was also used in combination with 
pertussis toxin. This allowed scientists to create fluctuating symptoms that 
could be used to model relapsing-remitting MS. More recently, scientists 
have replaced the brain proteins used to induce EAE with encephalitogen-
ic peptides, which are short polymers of amino acids capable of producing 
EAE. It is interesting to note that this method of antigen application has an 
effect on the type of EAE induced (Mix et al., 2010, p. 387). In addition, 
the age, sex, antigen employed, dose, species and the commercial source of 
the animals also influence the type and level of EAE that is induced (Teixe-
ria, 2005, p. 128). The varieties of EAE models that can be produced help 
scientist study different aspects of MS. For example, some rats are gener-
ally prone to developing an acute form of EAE with spontaneous recovery 
while others show predictable clinical symptoms (Teixeria, 2005, p. 128). 
This available variation is very important to the testing because it allows 
scientists to explore how to treat different phases of multiple sclerosis. 
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The EAE murine model and human MS share many other similari-
ties that make the EAE model an acceptable model for MS. In both cas-
es, genetic susceptibility is strongly linked with major histocompatibility 
complex class II molecules, which tell white blood cells which molecules 
are foreign and which belong to the body (Steinman and Zamvil, 2005, p. 
568). In addition, they share similar molecular pathways. The “fundamen-
tal mechanisms underlying oligodendrocyte development and myelination 
[when observed] are closely conserved between mouse and human” (Mill-
er and Fyffe-Maricich, 2010, p. 536). One of the many molecular cues that 
mice and humans share causes the production and proliferation of oligo-
dendrocytes, a type of glial cell in the central nervous system that insulates 
axons. These cells develop from inductive signals by neural stem cells. In 
addition, myelination of axons in both humans and mice is done in a very 
specific sequence (Miller and Fyffe-Maricich, 2010, p. 536). Finally, the 
disease induction is similar in both EAE and MS, where similar T cells, 
antibodies, and complements can be found in the lesions of both diseases 
(Steinman and Zamvil, 2005, p. 568).
W e a k n e s s e s  o f  t h e  E A E  M u r i n e  M o d e l
This is not to say that the EAE model is without flaws. It is important 
to note that EAE is not an animal version of multiple sclerosis; rather it 
is only a model for the human disease.  First and foremost, MS is a spon-
taneously occurring disease with an unknown trigger. On the other hand, 
EAE is an induced disease with a very specific cause (‘t Hart et al., 2011, p. 
120). It is also a short term model, thus experiments are often conducted 
within a few weeks or months. In contrast, human MS takes much longer 
to develop (Baker et al., 2011, p. 649-653). For these reasons, the EAE 
murine model may not accurately correspond with the pathology of MS 
or its presentation over time.   
 There are also some inherent differences in the way that MS and 
EAE operate. One of the biggest challenges is a basic difference in pathol-
ogy between human MS and rat EAE. Because the symptoms in EAE rats 
arise mainly due to inflammation and edemas rather than an autoimmune 
response, demyelination, a major component of MS, is rarely observed in 
rats (Teixeria, 2005, p. 128). Demyelination is sometimes noted in long 
term studies of the model (Baker et al., 2011, p. 649-653), but most studies 
are not of long duration. Additionally, in many cases EAE murine models 
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are unlikely to develop brain lesions, an important factor used in diagnos-
ing the depth of human MS, due to the fact that brain scans can be done 
on a living patient. Instead, the spinal cords of rats are used to determine 
the depth of EAE present as they provide more definitive results. These 
variations between murine EAE and human MS enlarge the immunother-
apy gap.  
Although some of the inherent differences in the various EAE murine 
models do not reflect MS progression, changing the experimental process 
might lead to more relevant results. One of the important differences rests 
in the type of T-cells that are active in the lesion areas. T-cells are responsi-
ble for engaging macrophages or destroying virally infected cells. By doing 
this, they are responsible for much of the damage that occurs to the axons 
in the body. In the lesion areas of the murine model, the predominant 
type of T-cells found is CD4+. However, in human MS patients, CD8+ 
T-cells are more abundant (‘t Hart et al., 2011, p.120). This means that, 
at times, drugs that work in the murine model because they utilize CD4+ 
T-cells do not work as well in human patients. Glatiramer acetate, which 
was approved for use by the FDA in 1996, is one of the few drugs that 
has successfully translated from the EAE murine model to human patients 
because it utilizes both CD4+ and CD8+ T-cells (Lalive et al., 2011, p. 
401-411) as targets. Therefore, it is able to work in both body systems. It is 
important that researchers acknowledge these differences and subsequent-
ly test therapies to ensure that they will, in fact, work with both immune 
systems, rather than just target a single type of T-cell.
T h e  I m m u n o t h e r a p y  G a p
This brings about the question, what is it that causes the immunother-
apy gap? There are several parameters including the model’s poor ability 
to indicate toxicity, the use of CFA in studies, the genetic background of 
knockout mice, the experimental conditions (environment) and the testing 
practices (timing, sample size) involved in experimentation with the mu-
rine model. However, by implementing certain changes, it is possible to 
reduce the immunotherapy gap. 
T o x i c i t y
At times, the murine EAE model is a poor indicator of a therapy’s tox-
icity in humans due to a general lack of detailed toxicology testing in EAE 
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experiments (Steinman and Zamvil, 2005, p. 565-269). Since many exper-
iments with the murine model are done over the span of a few weeks and 
experiments that are considered long term only last several months, toxic 
effects that often show up in studies that span years are not accounted for. 
 Natalizumab is an example where drug toxicity (and risk of infec-
tion) was not noticed in the EAE model. The drug was at first approved 
by the FDA, but later taken off the shelves because it caused progressive 
multifocal leukoencephalopathy (PML), which may be fatal in some cases. 
The fact that Natalizumab increases the risk for PML could not have been 
known using just the EAE murine model, as the virus that causes PML 
does not affect most mice species (Steinman and Zamvil, 2005, p. 569). 
One change in experimental design that might help overcome this inade-
quacy would be to test drugs on multiple animal models, such as monkeys 
or marmosets, rather than just on the murine model.  
On the other hand, there are some drugs whose toxicity might have 
been predicted using the EAE murine model had experimental procedures 
been different. Quinoline carboxamide or Linomide is another drug that 
worked effectively in reducing disease in the EAE murine model. In the 
beginning, this drug helped MS patients by reducing MR activity in MRI 
scans, but it was withdrawn due to cardiotoxcicity in the human trials. 
Only after years of testing could other drugs like Linomide be adminis-
tered to humans without cardiotoxic effects (Steinman and Zamvil, 2005, 
p. 569). Had these EAE studies been done on more animals over longer 
periods of time, with detailed toxicology studies done in each trial, the 
toxic effects may have been noticed before the therapies reached humans. 
T h e  B l o o d  B r a i n  B a r r i e r
The blood brain barrier (BBB) is a system within the human body that 
helps the central nervous system maintain homeostasis (Bennett et al., 
2010, p. 180). Many drugs, including drugs targeting MS, must be per-
meable to the blood brain barrier in order to be effective. As a result, the 
therapies most affected by a difference in permeability w¬ould be those 
targeting cytokines, which are cell-signaling protein molecules that work 
by infiltrating the CNS (Mix et al., 2010, p. 395). There is a difference in 
blood brain barrier permeability between the murine and human models 
and some scientists feel that the difference in blood brain barrier perme-
ability between these two models causes problems (Zhang et al., 2011, 
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p. 6). However, Bennett et al. stated that the permeabilities are actually 
comparable (Bennett et al., 2010, p. 190). In addition, scientists from the 
University of British Columbia studied the adaptor protein zonula occu-
ludens (ZO-1) in the tight junctions of MS patients and EAE models. Tight 
junctions help control the flow of elements between circulating blood and 
the brain’s fluids in the CNS. They chose to study the ZO-1 protein be-
cause it is abnormally disrupted due to varying BBB permeabilities. They 
found that these proteins reorganized themselves before EAE was induced. 
Overall, their study showed that junction pathology between MS patients 
and EAE rats are very similar (Bennett et al., 2010, p. 180-190), which 
means that the BBB permeabilities are also similar. Nonetheless, it is im-
portant to note that the use of certain experimental conditions increase 
BBB permeability in animals, which influences data interpretation (Teixei-
ra et al., 2005, p. 129). 
It is most likely the use of adjuvants that causes the differences (Teix-
eira et al., 2005, p. 129). In the murine EAE model, certain adjuvants are 
used to increase the blood brain barrier’s permeability, affecting the inter-
pretation of data. If the BBB in the murine model has greater permeability 
than the BBB in humans, medicines would more easily reach target areas 
in the murine model. Therefore, when the dose is converted for humans, 
the therapy dose would be incorrect, or inefficient. Simply giving humans 
patients a larger dose may not always be an option, as more medicine may 
mean an increase in detrimental side effects and toxicity. 
C o m p l e t e  F r e u n d ’ s  A d j u v a n t 
It may be the use of Freund’s adjuvant and not the actual BBB permea-
bility that is the problem. Most experiments dealing with the EAE murine 
model call for the use of Complete Freund’s adjuvant (CFA) to boost 
the inflammation reaction. This solution is simply an antigen emulsified 
in mineral oil, which includes inactivated and dried mycobacteria. CFA 
works by causing an antigen to exist in the body longer as it changes im-
munological tolerance, which in turn allows EAE to manifest itself in the 
murine model more clearly. CFA is used in certain murine models that are, 
at times, more resistant to EAE (Tiexeira, 2005, p. 132). CFA is known to 
affect the induction of EAE in the murine model, thereby changing how 
the CNS reacts. When testing instances that involve an autoimmune re-
sponse, this model is farther from the true MS than a murine EAE model 
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without the use of CFA. This may, for example, affect testing with human 
MS since it is an autoimmune disease (Tiexeira, 2005, p. 129-130). CFA is 
also known to increase BBB permeability (Tiexeira, 2005, p. 129). There-
fore, CFA may be the cause for the difference in therapy absorption be-
tween the murine model and human MS that is seen in some tests. 
There are ways to avoid the use of CFA by making some simple chang-
es to the way the experiment is conducted. For example, in mice with a 
high tolerance against EAE, passive induction can be used to eliminate the 
need for CFA. In this process, clones of epitope-specific encephalytogenic 
T cells from immunized animals, which can cause brain inflammation, are 
used to induce EAE (Tiexeira, 2005, p. 130). By reducing the use of CFA, 
it is possible to produce comparable BBB permeabilities between EAE and 
MS thus providing more accurate results in EAE testing.
K n o c k  O u t  M i c e
Some problems that create the immunotherapy gap stem from the types 
of mice used for testing. One variety of mice and rats that scientists use for 
experiments are “knock out” mice. Knock out mice are a variety of genet-
ically modified animals that have had one or more segment of their DNA 
removed. The pieces of removed DNA often turn off certain functions 
in the mice, sometimes for their entire lives. Due to this, knock out mice 
can have abnormal body structures such as “abnormal spleen architecture, 
blood lymphocytosis, absence of lymph nodes, and functional defects in T 
cell physiology” (Steinman, 1997, p. 2039). These deficiencies affect their 
body functions when tests are conducted, convoluting data interpretation 
when comparing to human MS. 
The genetic code has many redundancies. Consequently, when one 
portion is removed, other pieces take over the function and fill in the gap. 
This is especially a problem in experiments dealing with cytokines, which 
are cell-signaling molecules, because cytokines often have diverse func-
tions. Redundancy of TNF-α is another important factor when consider-
ing the use of knock out mice. TNF-α is a tumor necrosis factor whose 
blockade may or may not help MS patients’ symptoms (Steinman and 
Zamvil, 2005, p. 567). Knock out mice were used to show that TNF-α 
has a redundant function, meaning that the removal of the loci that cre-
ates TNF-α does not change how the mouse functions (Steinman, 1997, 
p. 2039-2040).. Although this is a very important discovery, scientists are 
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unable to use knock out mice to study the effects of TNF-α because they 
have no way to work around the redundancy in the code. 
Although knock out mice have their pitfalls, their flaws can be over-
come and therefore they may be useful for certain types of testing (Mix et 
al., 2010, p. 389). Perhaps it is best to use knock out mice to test pathways 
in MS, rather than using them to test the efficiency of a therapy. By find-
ing pathways through which the disease works, researchers can find other 
possible ways to treat MS. 
T i m i n g
Many of the practices that scientists use when testing with animals 
cannot possibly be replicated in humans, thereby creating a large gap in 
results between the two groups. These practices involve measuring the ef-
fectiveness of therapies on induction versus progression of the disease. For 
example, several successful therapies worked best to block induction of 
the disease when administered to mice before EAE symptoms arose. How-
ever, this cannot be done with humans, as MS cannot be diagnosed before 
symptoms appear. Yet still, approximately forty-eight percent of therapies 
are administered before EAE induction, twenty-two percent on the day of 
induction, and thirty percent right after induction in many murine model 
testing. Only about four percent of studies are started two weeks after in-
duction and less than one percent are started three weeks after induction 
(Vesterinen et al., 2010, p. 1052). Many of the therapies are tested in the 
early stages of EAE but are often used in later time periods for MS patients. 
This detrimentally affects translation (Baker et al., 2011, p. 648-653). In 
order to better reflect real life circumstances, more tested therapies should 
be administered in the later stages of EAE.  
There are also differences in how the efficiency of a therapy is measured 
in each instance. For human patients, success is based on relapse frequency 
and the slowing of disease progression. Yet in the EAE murine models, 
success is often based on the severity of the initial illness, as drugs are 
given before EAE is induced. This means that some of the EAE therapies 
that are a success actually work by blocking the induction of the disease. 
Experiments conducted after the induction of EAE had lower efficiency 
rates, meaning they were overall less successful. (Vesterinen et al., 2010, 
p. 1052). Therefore, only the results of trials started after induction should 
be employed in a clinical setting. When this is done in combination with 
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testing later, after EAE induction, results will be more in line with possible 
results in human MS testing. 
E n v i r o n m e n t
The environments that the mice and rats live in contribute to the im-
munotherapy gap since the life of a lab animal does not reflect the human 
condition. Although the EAE model can exhibit the complexity of MS, 
there is very little genetic variety within a murine population being tested 
due to inbred strains (Steinman and Zamvil, 2005, p. 565). This poses a 
problem as EAE shows itself in different manners based on genetics. In 
addition to a lack of genetic variation within a population, a controlled en-
vironment also often means a very clean and sterile environment (‘t Hart 
et al., 2011, p. 120). As a result, the murine EAE models are often poor 
indicators of both the risk of infection and the toxicity of the therapy in 
humans. In addition, most lab mice and rats are kept in a very controlled 
environment. This is done specifically to ward off infection and other con-
taminants that might affect the end results of an experiment. Consequent-
ly, this also means that scientist cannot test if and how a therapy increases 
the risk of infection for a human with MS who cannot be kept in a sterile 
environment. For example, PML, which caused Natalizumab to be pulled 
from the shelves, generally only affects patients whose immune systems 
are compromised, such as those with AIDS. Since the lab rats are kept in 
a sterile environment and are healthy except for the induced disease, their 
risk of contracting infection would not be registered nor would these ani-
mals truly have compromised immune systems. This, in combination with 
other experimental practices, would make side effects such as infection 
nearly impossible to detect in the murine EAE model.
E x p e r i m e n t a l  D e s i g n
 In order to decrease the immunotherapy gap, several more changes 
to the experimental design need to be made in projects that deal with the 
EAE murine model. Scientists and researchers should use blinding, ran-
domization, conflict of interest statements, power analysis, and ethical re-
view in all EAE testing (Baker et al., 2011, p. 648). Blinding is a procedure 
in which certain researchers are prevented from knowing which subjects 
are given which treatment. This prevents subconscious prejudices from 
affecting the results. Randomization is a method where treatments are 
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randomly given across a test group, which helps reduce bias. Conflict of 
interest statements are often already listed and provide information about 
any factors that could cause undue bias in an experiment. Power analysis 
is a statistical calculation that informs scientists about the minimum sam-
ple size that they will need in an experiment in order to detect the effect 
of the experiment correctly. Ethical review of experiments is also very 
important since it depends on ethics guidelines that frequently inform sci-
entists how to administer adjuvants, such as CFA, or how to treat animals. 
Ethics may also deal with various stressors introduced to animals, which 
can often affect the outcome of an experiment. All of these processes are 
required when conducting experiments on humans, but are not currently 
required when researching solely with animals (Baker et al., 2011, p. 652). 
Thus experimental design procedures should be reformed to decrease the 
immunotherapy gap. 
Vesterinen et al. (2010) completed a thorough review of experiments 
done with EAE. The scientists researched the frequency of certain practic-
es in EAE experiments. Of the papers studied, randomization was present 
in only nine percent, blinding in sixteen percent, power calculation in less 
than one percent, compliance with animal welfare regulation in thirty-two 
percent, and potential conflicts were listed in six percent of the publications 
(Vesterinen et al., 2010, p.1046). However, it is important to note that 
compliance with animal regulations has been on the rise and that studies 
that were randomized and blinded had lower rates of efficacy than those 
that were not (Vesterinen et al., 2010, p. 1052). Specifically, not blinding 
an experiment can lead to a thirty percent overestimation of efficiency. 
Of all the studies Vesterinen et al. looked at, only two of them stated 
that they had conducted a power analysis calculation in order to determine 
sample size. Vesterinen et al. (2010) found that most of the test groups in 
the experiments were at least sixty-three percent smaller than power calcu-
lations indicated that they should be. Furthermore, most of the studies had 
test groups that only had five test subjects and control groups that only 
had eight subjects. 
Some of the most important steps researchers can take to close the 
immunotherapy gap are “randomization, allocation concealment and the 
blinded assessment of outcome; … sample size calculations and…preclin-
ical testing… focus[ing] on testing efficacy under clinically relevant condi-
tions including the initiation of treatment at some time after the induction 
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of injury, using models which are specifically designed to reflect the com-
plexities of the human disease” (Vesterinen et al., 2010, p. 1054). It may 
also be pertinent to study the murine EAE subjects for longer periods of 
time in order to gauge the long term effects of drugs as sometimes poten-
tial therapies may only postpone the onset of EAE for a few days (Baker 
et al, 2011, p. 653).
Conclusion
The EAE model is a very useful tool in research for multiple sclerosis. 
It has produced several drugs that have been of much use to multiple scle-
rosis patients. It has also provided insightful information on the pathways 
and chemical reactions at work in MS. In addition, the EAE murine mod-
els have often been used to test combinations of drugs in order to search 
for side effects. For example, the models helped find that Natalizumab, 
when combined with IFN-ß, could be fatal (Teixeria, 2005, p. 128). 
However, there are some discrepancies between human multiple scle-
rosis and the murine EAE model, such as the abundance of CD4+ T cells 
in EAE models and CD8+ T cells in human lesions. 
Much of the immunotherapy gap is created by experimental procedure. 
Whether it is giving murine test subjects a dose that is known to be too 
high to be replicated or providing them with the therapy before EAE has 
been induced, research practices with the murine model do not parallel 
research practices used in human MS patients. Therefore, it is not expect-
ed that the results of such experiments will be the same in both the EAE 
models and MS patients. 
In order to shrink the immunotherapy gap, EAE testing and MS test-
ing must become more aligned in practice. Blinding, randomization, pow-
er calculations, toxicology reports, conflict of interest statements, proper 
medicating periods, and ethics reviews must be made standard for murine 
model testing when dealing with MS testing, just as it is required for hu-
man patients. Without these experimental procedures, the efficiency rates 
will be highly disproportional to the actual truth.
These procedures will also decrease the chance that false positives will 
reach the clinical stage of testing. In addition, the current inadequacies of 
testing force money and time to be funneled to experiments that will never 
go anywhere. Some of the therapies may even be harmful to the health of 
multiple sclerosis patients. By changing experimental practices, scientists 
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could reduce the immunotherapy gap that exists between the murine EAE 
model and human MS. 
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